Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

Neptune Technologies & Bioresources' (NEPT) CEO Jim Hamilton on Q3 2018 Results - Earnings Call Transcript

2018-02-15 seekingalpha
Neptune Technologies & Bioresources Inc. (NASDAQ:NEPT) Q3 2018 Earnings Conference Call February 14, 2018 5:00 PM ET (4-1)

Neptune and Tetra Bio-Pharma Enter Co-Development Agreement for Purified Cannabinoid Oil-Based Products targeting Pain and Inflammation

2018-02-12 marketwired
LAVAL, QUÉBEC--(Marketwired - Feb. 12, 2018) - Neptune Technologies & Bioressources Inc. ("Neptune") (NASDAQ:NEPT)(TSX:NEPT) and Tetra Bio-Pharma Inc. ("Tetra") (TSX VENTURE:TBP)(OTCQB:TBPMF) today announced that they entered into an agreement for the co-development, commercialization and marketing of purified cannabinoid oil-based products to address pain and inflammation relief applications for the natural health products and pet veterinary markets. (4-0)

Neptune and Tetra Bio-Pharma Enter Co-Development Agreement for Purified Cannabinoid Oil-Based Products targeting Pain and Inflammation

2018-02-12 marketwired
LAVAL, QUÉBEC--(Marketwired - Feb. 12, 2018) - Tetra Bio-Pharma Inc. ("Tetra") (TSX VENTURE:TBP)(OTCQB:TBPMF) and Neptune Technologies & Bioressources Inc. ("Neptune") (NASDAQ:NEPT)(TSX:NEPT) today announced that they entered into an agreement for the co-development, commercialization and marketing of purified cannabinoid oil-based products to address pain and inflammation relief applications for the natural health products and pet veterinary markets. (4-0)

RETRANSMISSION: Tetra Bio-Pharma Receives Health Canada Phase 3 Clinical Trial Approval For Smokable Dried Cannabis Prescription Drug

2018-02-05 marketwired
OTTAWA, ONTARIO--(Marketwired - Feb. 5, 2018) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce that it has received a No Objection Letter (NOL) from the Therapeutic Products Directorate (TPD) Health Canada to its Clinical trial application (CTA) for the Company's PPP001 prescription smokable dried cannabis product. (9-0)

Tetra Bio-Pharma Receives Health Canada Phase 3 Clinical Trial Approval For Smokable Dried Cannabis Prescription Drug

2018-02-04 marketwired
OTTAWA, ONTARIO--(Marketwired - Feb. 4, 2018) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce that it has received a No Objection Letter (NOL) from the Therapeutic Products Directorate (TPD) Health Canada to its Clinical trial application (CTA) for the Company's PPP001 prescription smokable dried cannabis product. (9-0)

Tetra Bio-Pharma Receives Health Canada Approval for Phase 2 Cannabis Oil Trial in Partnership with Sante Cannabis

2018-01-29 marketwired
OTTAWA, ONTARIO--(Marketwired - Jan. 29, 2018) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce the approval by Health Canada of a Phase 2 clinical trial designed to evaluate the safety and efficacy of different doses and ratios of medical cannabis oil (THC & CBD) to improve uncontrolled chronic pain in cancer and non-cancer patients. (3-0)

Tetra Bio-Pharma Receives Approval from Health Canada of its Phase 1 Clinical Trial with PPP005 (Cannabis Oil)

2018-01-16 marketwired
OTTAWA, ONTARIO--(Marketwired - Jan. 16, 2018) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce that it has received a No Objection Letter (NOL) from the Therapeutic Products Directorate (TPD), Health Canada to evaluate the safety, pharmacokinetics and pharmacodynamics of its cannabis oil PPP005. (9-0)

Tetra Bio-Pharma Enters into Agreement to Acquire Remaining 20% Interest in Phytopain Pharma Subsidiary

2018-01-02 marketwired
OTTAWA, ONTARIO--(Marketwired - Jan. 2, 2018) - Bio-Pharma Inc. ("Tetra" or the "Corporation") (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development, today announced that it has entered into a share purchase agreement (the "Purchase Agreement") with entities controlled by André Rancourt, Chairman of the Board of Directors of the Corporation, and Guy Chamberland, Chief Scientific Officer of the Corporation (collectively, the "Vendors"). (3-0)

Tetra Bio-Pharma Announces the Signature of a Letter of Intent to Monetize GrowPros and its Late Stage ACMPR Application

2017-12-21 marketwired
OTTAWA, ONTARIO--(Marketwired - Dec. 21, 2017) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce that it has entered into a non-binding letter of intent (the "LOI") with a private Canadian corporation (the "Purchaser") and has started a transaction to monetize GrowPros (GrowPros MMP Inc. (3-0)

Tetra Bio-Pharma Reinforces its Development Program by Signing Research & Development Agreement with Constance Therapeutics and Receiving Financial Support from NSERC

2017-12-13 marketwired
OTTAWA, ONTARIO--(Marketwired - Dec. 13, 2017) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce that the company has signed an exclusive research and development (R&D) agreement with Constance Therapeutics for the pharmaceutical drug development, and eventual commercialization in Canada, of their standardized, patent-pending, medicinal cannabis extract products. (3-0)

Tetra Bio-Pharma provides update on status of its Phase 3 Clinical Trial Application of Lead Drug Candidate PPP001

2017-12-09 marketwired
OTTAWA, ONTARIO--(Marketwired - Dec. 9, 2017) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development, announced today that the Company has accepted the suggestion of Health Canada to change the order of its clinical trial application (CTA) review process. As such, the quality certification for the manufacturing of PPP001 will take place prior to the approval of its clinical trial protocol as Health Canada assesses its partner Aphria's operations for Good Manufacturing Practices (GMP) for pharmaceutical products. (3-1)

Tetra Bio-Pharma Opens Markets at TSX Listing Ceremony

2017-12-06 marketwired
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development, is pleased to announce that Tetra opened the Toronto Stock Exchange ("TSX") yesterday at a ceremony to recognize the listing and trading of Tetra, which began on August 16th 2017 under the symbol TBP. The listing ceremony took place at the TMX Broadcast Centre in Toronto, Ontario. (3-0)

Tetra Bio-Pharma accelerates submission of New Drug Application to FDA & Expects to Commercialize Dronabinol XL Tablet Ahead of Schedule(1) in the US

2017-11-28 marketwired
OTTAWA, ONTARIO--(Marketwired - Nov. 28, 2017) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP) (OTCQB:TBPMF), a global leader in cannabinoid-based drug development, today announced that it is partnering with a major manufacturer of controlled active pharmaceutical ingredients (APIs) in the USA for the manufacturing of Dronabinol XL AdVersa® as the Company accelerates its plans to submit a 505(b)(2) New Drug Application (NDA) for the treatment of chemotherapy-induced nausea and vomiting (CINV) and anorexia associated with weight loss in patients with AIDS. (18-0)

Tetra Bio-Pharma's Business Model and Commercialization Strategy In Line with the Canadian Government's Proposed Approach to the Regulation of Cannabis

2017-11-22 marketwired
OTTAWA, ONTARIO--(Marketwired - Nov. 22, 2017) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced that the Canadian Government's Proposed Approach to the Regulation of Cannabis further confirms the strategic direction of its business model, and that the company is in an excellent position to commercialize natural health products and drugs post-legalization for both the pet and human markets. (3-0)

Tetra Bio-Pharma Inc.: Rx Princeps(TM) Now Available for Patients through Licenced Producer Partner Aphria

2017-11-16 marketwired
OTTAWA, ONTARIO--(Marketwired - Nov. 16, 2017) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced that Rx Princeps™, unique blend of dried medical cannabis used in its PPP001 clinical trials, is now available through licensed producer Aphria Inc. ("Aphria") under Access to Cannabis for Medical Purposes Regulations (ACMPR). (9-0)


CUSIP: 39985Y102